Elbion AG reeled in €25 million in Germany's first significant biotech financing of 2005. The company, which was formed through a management buyout of some of Degussa AG's pharmaceutical assets in 2002, concentrates on the discovery and development of small molecules that are effective against inflammatory and central nervous system diseases. (BioWorld International)
Elbion AG reeled in €25 million in Germany's first significant biotech financing of 2005. The company, which was formed through a management buyout of some of Degussa AG's pharmaceutical assets in 2002, concentrates on the discovery and development of small molecules that are effective against inflammatory and central nervous system diseases. (BioWorld International)
MUNICH, Germany - MediGene AG completed its second Phase III trial of Polyphenon E, a treatment for genital warts, getting significant clinical effects compared to placebo, as well as good tolerability. (BioWorld International)
MUNICH, Germany - MediGene AG completed its second Phase III trial of Polyphenon E, a treatment for genital warts, getting significant clinical effects compared to placebo, as well as good tolerability. (BioWorld International)
